NOD2 mutations and colorectal cancer - Where do we stand?

Table 1 Genotype frequencies of the nucleotide-binding and oligomerization-domain containing 2 polymorphisms

	Country	Finland[36]	Greece[40]	Hungary[39]	New Zealand[43]	Portugal[38]
	CRC (n)	953/960/9261	104	194	133	112
	Controls (n)	508/508/3481	100	200	201	152
R702W
CRC	% Allele frequency	2.2	4.8	1.8	7.1	12.5
Control	% Allele frequency	2.1	1.0	1.5	3.0	5.3
	P value	0.88	0.02	0.78	0.03	0.03
G908R
CRC	% Allele frequency	0.3	8.65	1.8	2.2	2.73
Control	% Allele frequency	0.2	3.5	1.8	0.8	3.29
	P value	0.57	0.025	0.95	0.09	0.77
3020insC
CRC	% Allele frequency	1.9	12.5	3.6	2.2	0.89
Control	% Allele frequency	1.9	6	2.5	1.0	1.3
	P value	0.96	0.017	0.40	0.19	0.75
At least one mutation
CRC	% Genotype frequency	-	51.9	14.4	21.8	16.1
Control	% Genotype frequency	-	21.0	11.5	8.9	9.9
	P value	-	< 0.0001	0.45	0.001	0.132

¹CRC cases and controls for each mutation, respectively (R702W, G908R, 3020insC). CRC: Colorectal cancer.

Table 2 Nucleotide-binding and oligomerization-domain containing 2 polymorphisms and cancer risk: Results of meta-analysis

Meta-analysis		Liu et al[37] (2014)	Tian et al[41] (2010)
R702W
Variant genotypes vs homozygous wild-type	OR	1.32	1.59
	95%CI	1.01-1.72	1.09-2.32
	P value	0.04	0.02
G908R
Variant genotypes vs homozygous wild-type	OR	1.32	1.98
	95%CI	1.01-1.72	1.14-3.44
	P value	0.04	0.01
3020insC
Variant genotypes vs homozygous wild-type	OR	1.23	1.44
	95%CI	1.10-1.38	1.13-1.84
	P value	< 0.001	0.003
R702W/G908R/3020insC
Variant genotypes vs homozygous wild-type	OR	-	1.58
	95%CI	-	1.03-2.42
	P value	-	0.03

OR: Odds ratio.